Company: CI
Filing Date: 2025-06-02
Form Type: 8-K
Source: 0001140361-25-021143
Chunk: 0

Company: Cigna Group
Filing Date: 2025-06-02
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory  

On May 30, 2025, the board of directors (the “ Board”) of The Cigna Group (the “ Company”) appointed Michael J. Hennigan as an independent member of the Board, effective
June 2, 2025.

Mr. Hennigan will participate in the Company’s non-employee director compensation program, amended and restated effective July 24, 2024 (the “ Plan”), as described in the
Company’s Proxy Statement for the 2025 Annual Meeting of Shareholders, filed with the Securities and Exchange Commission (the “ SEC”) on March 14, 2025. A copy of the Plan has been filed as Exhibit 10.14(c) to the Company’s Annual Report on Form
10-K for the year ended December 31, 2024, filed with the SEC on February 27, 2025.

There is no arrangement or understanding between Mr. Hennigan and any other person pursuant to which Mr. Hennigan was selected as a director. There have been no
transactions involving Mr. Hennigan that would be required to be disclosed by Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended.

The Company will file an amended Form 8-K to disclose Mr. Hennigan’s committee assignments once determined.

A copy of the Company’s press release announcing the appointment of Mr. Hennigan is attached to this report as Exhibit 99.1 and incorporated herein by reference.